About Sherri-Ann Burnett-Bowie, MD, MPH

Sherri-Ann M. Burnett-Bowie MD, MPH is an Assistant Professor of Medicine at Harvard Medical School and a clinical investigator in the Massachusetts General Hospital (MGH) Endocrine Unit, where her research focuses on  skeletal and non-skeletal effects of vitamin D, and clinical trials of treatments for osteoporosis.  She cares for patients seen at the MGH Endocrine Associates and the MGH Bone Density Center.  Dr. Burnett-Bowie is an Associate Director of the MGH Center for Diversity and Inclusion and the Director of Multicultural Affairs for the Department of Medicine at MGH.  Teaching and increasing diversity and inclusivity are central to her mission.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Endocrine Associates
15 Parkman Street
Boston, MA 02114-3117
617-726-8720
Fax: 617-724-2718

Medical Education

  • MPH, Harvard T. H. Chan School of Public Health
  • MD, University of Pittsburgh School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Endocrinology,

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Burnett-Bowie's  research is focused on skeletal and non-skeletal consequences of vitamin D deficiency, and clinical trials of treatments for osteoporosis.

Publications

  • View my most recent publications at PubMed

    Select Publications:

    • Burnett, SM, S Gunawardene, FR Bringhurst et al.  Regulation of c-terminal and intact FGF23 by dietary phosphate in men and women.  JBMR 2006.
    • Burnett-Bowie, SM , BZ Leder, MP Henao et al. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. CJASN 2012.
    • Mitchell, DM, MP Henao, JS Finkelstein, SM Burnett-Bowie. Prevalence & predictors of vitamin D deficiency in healthy adults. JCEM 2012.
    • Tsai, JN, Uihlein, AV, H Lee et al. Teriparatide & denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013
    • Finkelstein , JS, H. Lee, SM Burnett-Bowie et al. Gonadal steroids & body composition, strength, and sexual function in men. NEJM 2013